Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 1
2013 1
2014 2
2015 1
2016 1
2017 4
2018 4
2019 3
2020 5
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Vazquez C, Friedlaender A, Vuilleumier A, Bodmer A, Viassolo V, Sandoval JL, Chappuis PO, Labidi-Galy SI. Hu-Heimgartner K, et al. Among authors: viassolo v. Fam Cancer. 2023 Jul;22(3):283-289. doi: 10.1007/s10689-023-00331-6. Epub 2023 Apr 29. Fam Cancer. 2023. PMID: 37119509 Free PMC article. Review.
Prenatal diagnosis of Gollop-Wolfgang Complex.
Forzano F, Viassolo V, Castagnetta M, Cavani S, Battistuzzi L, Garbati E, Emiliozzi MC, Cecchi A, Faravelli F, Lituania M. Forzano F, et al. Among authors: viassolo v. Prenat Diagn. 2009 Jul;29(7):724-6. doi: 10.1002/pd.2269. Prenat Diagn. 2009. PMID: 19353531 No abstract available.
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI. Friedlaender A, et al. Among authors: viassolo v. Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11. Breast Cancer Res Treat. 2019. PMID: 30635808
A new bioinformatics tool to help assess the significance of BRCA1 variants.
Cusin I, Teixeira D, Zahn-Zabal M, Rech de Laval V, Gleizes A, Viassolo V, Chappuis PO, Hutter P, Bairoch A, Gaudet P. Cusin I, et al. Among authors: viassolo v. Hum Genomics. 2018 Jul 11;12(1):36. doi: 10.1186/s40246-018-0168-0. Hum Genomics. 2018. PMID: 29996917 Free PMC article.
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.
Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I. Labidi-Galy SI, et al. Among authors: viassolo v. Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30. Clin Cancer Res. 2018. PMID: 29084914
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. De Talhouet S, et al. Among authors: viassolo v. Sci Rep. 2020 Nov 2;10(1):19248. doi: 10.1038/s41598-020-76385-8. Sci Rep. 2020. PMID: 33139817 Free PMC article.
26 results